

ChemoCentryx, Inc.  
Form 10-Q  
May 14, 2013  
Table of Contents

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 10-Q**

x **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended March 31, 2013

Or

.. **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from            to

Commission File Number: 001-35420

**ChemoCentryx, Inc.**

(Exact Name of Registrant as Specified in Its Charter)

Edgar Filing: ChemoCentryx, Inc. - Form 10-Q

**Delaware**  
(State or Other Jurisdiction of  
Incorporation or Organization)

**94-3254365**  
(I.R.S. Employer  
Identification No.)

**850 Maude Avenue**

**Mountain View, California 94043**

(Address of Principal Executive Offices) (Zip Code)

**(650) 210-2900**

(Registrant's Telephone Number, Including Area Code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer

Non-accelerated filer  (Do not check if a smaller reporting company) Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

The number of outstanding shares of the registrant's common stock, par value \$0.001 per share, as of May 6, 2013, was 42,618,592.

**Table of Contents**

**CHEMOCENTRYX, INC.**

**QUARTERLY REPORT ON FORM 10-Q**

**For the quarterly period ended March 31, 2013**

**Table of Contents**

**PART I. FINANCIAL INFORMATION**

Item 1.	<u>Financial Statements (Unaudited)</u>	
	<u>Condensed Consolidated Balance Sheets – March 31, 2013 and December 31, 2012</u>	3
	<u>Condensed Consolidated Statements of Operations – Three Months Ended March 31, 2013 and 2012</u>	4
	<u>Condensed Consolidated Statements of Comprehensive Loss – Three Months Ended March 31, 2013 and 2012</u>	5
	<u>Condensed Consolidated Statements of Cash Flows – Three Months Ended March 31, 2013 and 2012</u>	6
	<u>Notes to Condensed Consolidated Financial Statements</u>	7
Item 2.	<u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u>	12
Item 3.	<u>Quantitative and Qualitative Disclosures About Market Risk</u>	18
Item 4.	<u>Controls and Procedures</u>	19

**PART II. OTHER INFORMATION**

Item 1.	<u>Legal Proceedings</u>	20
Item 1A.	<u>Risk Factors</u>	20
Item 2.	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	20
Item 3.	<u>Defaults Upon Senior Securities</u>	20
Item 4.	<u>Mine Safety Disclosures</u>	20
Item 5.	<u>Other Information</u>	20
Item 6.	<u>Exhibits</u>	20

	<b><u>SIGNATURES</u></b>	21
--	--------------------------	----

**EXHIBIT INDEX**

**Table of Contents****PART I. FINANCIAL INFORMATION****Item 1. Financial Statements****CHEMOCENTRYX, INC.****CONDENSED CONSOLIDATED BALANCE SHEETS**

(in thousands except share and per share data)

	March 31, 2013 Unaudited	December 31, 2012
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	\$ 11,637	\$ 8,460
Short-term investments	64,268	94,234
Accounts receivable from related party	934	1,156
Prepaid expenses and other current assets	942	630
<b>Total current assets</b>	<b>77,781</b>	<b>104,480</b>
Property and equipment, net	1,315	1,421
Long-term investments	33,803	16,262
Other assets	287	160
<b>Total assets</b>	<b>\$ 113,186</b>	<b>\$ 122,323</b>
<b>Liabilities and Stockholders Equity</b>		
Current liabilities:		
Accounts payable	\$ 781	\$ 750
Accrued liabilities	5,440	6,267
Deferred revenue from related party	2,633	3,761
Current portion of equipment financing obligations	527	522
<b>Total current liabilities</b>	<b>9,381</b>	<b>11,300</b>
Noncurrent equipment financing obligations	233	379
Other non-current liabilities	287	298
<b>Total liabilities</b>	<b>9,901</b>	<b>11,977</b>
Stockholders equity:		
Preferred stock:		
Preferred stock, \$0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding;	0	0
Common stock, \$0.001 par value, 200,000,000 shares authorized at March 31, 2013 and December 31, 2012, respectively; 36,834,405 shares and 36,354,547 shares issued and outstanding at March 31, 2013 and December 31, 2012, respectively, net of shares subject to repurchase	37	36
Additional paid-in capital	247,653	244,513
Note receivable	(16)	(16)
Accumulated other comprehensive (loss) income	(7)	2
Accumulated deficit	(144,382)	(134,189)
<b>Total stockholders equity</b>	<b>103,285</b>	<b>110,346</b>

Total liabilities and stockholders' equity	\$ 113,186	\$ 122,323
--	------------	------------

See accompanying notes.

Table of Contents

## CHEMOCENTRYX, INC.

## CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

(unaudited)

	Three Months Ended March 31,	
	2013	2012
Revenues:		
Collaborative research and development revenue from related party	\$ 1,927	\$ 1,018
Operating expenses:		
Research and development	9,255	6,909
General and administrative	2,964	2,562
Total operating expenses	12,219	9,471
Loss from operations	(10,292)	(8,453)
Other income (expense):		
Interest income	116	103
Interest expense	(17)	(735)
Total interest income (expense), net	99	(632)
Net loss	\$ (10,193)	\$ (9,085)
Basic and diluted net loss per common share	\$ (0.28)	\$ (0.28)
Shares used to compute basic and diluted net loss per common share	36,611	32,931

See accompanying notes.

**Table of Contents**

**CHEMOCENTRYX, INC.**

**CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE LOSS**

**(in thousands)**

**(unaudited)**

	<b>Three Months Ended March 31,</b>	
	<b>2013</b>	<b>2012</b>
Net loss	\$ (10,193)	\$ (9,085)
Unrealized (loss) gain on available-for-sale securities	(9)	10
Comprehensive loss	\$ (10,202)	\$ (9,075)

**Table of Contents****CHEMOCENTRYX, INC.****CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS****(in thousands)****(unaudited)**

	<b>Three Months Ended March 31,</b>	
	<b>2013</b>	<b>2012</b>
<b>Operating activities</b>		
Net loss	\$ (10,193)	\$ (9,085)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation of property and equipment	142	159
Stock-based compensation	1,536	1,022
Amortization of premiums/discounts on investments, net	420	380
Noncash interest expense	(11)	408
Changes in assets and liabilities:		
Accounts receivable due from related party	222	13
Prepays and other current assets	(312)	(166)
Other assets	(127)	1,935
Accounts payable	31	1,021
Other liabilities	(846)	(1,069)
Deferred revenue	(1,128)	(1,017)
<b>Net cash used in operating activities</b>	<b>(10,266)</b>	<b>(6,399)</b>
<b>Investing activities</b>		
Purchases of property and equipment, net	(36)	(26)
Purchases of investments	(36,682)	(92,882)
Maturities of investments	48,697	22,849
<b>Net cash provided by (used in) investing activities</b>	<b>11,979</b>	<b>(70,059)</b>
<b>Financing activities</b>		
Proceeds from issuance of common stock	0	57,017
Proceeds from exercise of stock options	1,293	154
Proceeds from exercise of warrants	312	0
Payments on equipment financing obligations	(141)	(135)
<b>Net cash provided by financing activities</b>	<b>1,464</b>	<b>57,036</b>
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>3,177</b>	<b>(19,422)</b>
Cash and cash equivalents at beginning of period	8,460	40,155
<b>Cash and cash equivalents at end of period</b>	<b>\$ 11,637</b>	<b>\$ 20,733</b>
<b>Supplemental disclosures of cash flow information</b>		
Cash paid for interest	\$ 9	\$ 14
Non-cash financing activity:		
Issuance of common stock for settlement of convertible debt, including accrued interest	\$ 0	\$ 10,215
	See accompanying notes.	





**Table of Contents**

**CHEMOCENTRYX, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2013**

**(unaudited)**

**1. Description of Business**

ChemoCentryx, Inc. (the Company) commenced operations in 1997. The Company is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally administered chemokine-based therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company's principal operations are in the United States and it operates in one segment.

**Unaudited Interim Financial Information**

The financial information filed is unaudited. The Condensed Consolidated Financial Statements included in this report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for the fair statement of the results of operations for the interim periods covered and of the financial condition of the Company at the date of the interim balance sheet. The December 31, 2012 Condensed Consolidated Balance Sheet was derived from audited financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America (GAAP). The results for interim periods are not necessarily indicative of the results for the entire year or any other interim period. The Condensed Consolidated Financial Statements should be read in conjunction with the Company's financial statements and the notes thereto included in the Company's annual report on Form 10-K for the year ended December 31, 2012 filed with the Securities and Exchange Commission, or SEC, on March 14, 2013.

**2. Summary of Significant Accounting Policies**

**Use of Estimates**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates.

**Reclassifications**

Certain items in the Condensed Consolidated Statements of Cash Flows have been reclassified to conform to the current fiscal year's format.

**Net Loss Per Share**

Basic and diluted net loss per common share is computed by dividing net loss by the weighted-average number of vested common shares outstanding during the period. Participating securities are included in the computation of basic income per share using the two-class method. The calculation of diluted net loss per share excludes potential common stock because its effect is antidilutive. Potential common stock consists of incremental common shares issuable upon the exercise of stock options and warrants.

**Table of Contents**

For the three months ended March 31, 2013 and 2012, the Company's potential common stock includes the following shares, all of which have been excluded from the computation of diluted net loss per share because their impact is antidilutive:

	Three Months Ended March 31,	
	2013	2012
Options to purchase common stock	4,969,772	4,279,738
Warrants to purchase common stock	151,672	309,500
Common stock subject to repurchase	0	700
	5,121,444	4,589,938

**3. Cash Equivalents and Investments**

The amortized cost and fair value of cash equivalents and investments at March 31, 2013 and December 31, 2012 were as follows (in thousands):

	Amortized Cost	March 31, 2013 (unaudited) Gross Unrealized		Fair Value
		Gains	Losses	
Money market funds	\$ 12,093	\$ 0	\$ 0	\$ 12,093
Government-sponsored agencies	12,005	1	(1)	12,005
Commercial paper	25,378	0	0	25,378
Corporate debt securities	58,691	21	(28)	58,684
<b>Total available-for-sale securities</b>	<b>\$ 108,167</b>	<b>\$ 22</b>	<b>\$ (29)</b>	<b>\$ 108,160</b>

Classified as:

Cash equivalents	\$ 10,089
Short-term investments	64,268
Long-term investments	33,803

Total available-for-sale securities \$ 108,160

	Amortized Cost	December 31, 2012 Gross Unrealized		Fair Value
		Gains	Losses	
Money market funds	\$ 10,403	\$ 1	\$ 0	\$ 10,404
Government-sponsored agencies	6,009	1	0	6,010
Commercial paper	29,171	3	0	29,174
Corporate debt securities	71,980	23	(26)	71,977
<b>Total available-for-sale securities</b>	<b>\$ 117,563</b>	<b>\$ 28</b>	<b>\$ (26)</b>	<b>\$ 117,565</b>

Classified as:

Cash equivalents	\$ 7,069
Short-term investments	94,234

## Edgar Filing: ChemoCentryx, Inc. - Form 10-Q

Long-term investments	16,262
Total available-for-sale securities	\$ 117,565

All available-for-sale securities held as of March 31, 2013, had contractual maturities of less than two years. There have been no significant realized gains or losses on available-for-sale securities for the periods presented. No available-for-sale securities held as of March 31, 2013, have been in a continuous unrealized loss position for more than 12 months. As of March 31, 2013, unrealized



## Edgar Filing: ChemoCentryx, Inc. - Form 10-Q

The Company recorded its convertible debt as a liability at fair value, which was estimated at the issuance date using the Probability-Weighted Expected Returns model (PWERM). The PWERM requires inputs such as the expected term of the debt, share price volatility, risk-free interest rate and the likelihood and timing of future equity financing. These assumptions are reviewed each reporting period and changes in the estimated fair value of the convertible note are recognized in interest expense. As of December 31, 2011, the Company estimated the fair value of its convertible debt at approximately \$10.5 million. In February 2012, following the completion of the Company's initial public offering, or IPO, all outstanding principal and accrued interest relating to this debt automatically converted into 1,021,490 shares of common stock. The following table shows the change in fair market value of the Company's liabilities during the three months ended March 31, 2012 (in thousands):

**Table of Contents**

	Fair Market Value
Convertible debt from related party	
Balance as of December 31, 2011	\$ 10,472
Change in fair market value prior to conversion	794
Balance upon conversion	11,266
Balance as of March 31, 2012	\$

**5. Accrued Liabilities**

Accrued liabilities consist of the following (in thousands):

	March 31, 2013 (unaudited)	December 31, 2012
Research and development related	\$ 3,566	\$ 3,678
Compensation related	988	1,889
Other	886	700
	\$ 5,440	\$ 6,267

**6. Related-Party Transactions****Glaxo Group Limited**

In August 2006, the Company entered into a product development and commercialization agreement with Glaxo Group Limited (GSK). The Company recognized the following revenues from GSK during the three months ended March 31, 2013 and 2012 (in thousands):

	Three Months Ended March 31,	
	2013	2012
GSK:		
Contract revenue	\$ 799	\$ 0
Recognition of up-front payments	1,128	1,018
Total revenues	\$ 1,927	\$ 1,018

At March 31, 2013 and December 31, 2012, the Company had an accounts receivable balance due from GSK of \$0.9 million and \$1.2 million, respectively.

**Techne**

In September 2011, the Company entered into a convertible note loan agreement with Techne Corporation, or Techne, one of its principal stockholders, pursuant to which the Company issued a convertible note to Techne with a principal amount of \$10.0 million and bearing interest at a rate of 5.0% per annum and a maturity date in September 2021. In February 2012, the Company completed its IPO, and as such, all outstanding principal and accrued and unpaid interest automatically converted into 1,021,490 shares of common stock at a conversion price equal to the IPO price of \$10.00 per share. Upon the conversion of the note in connection with the IPO, Techne received a warrant with a

## Edgar Filing: ChemoCentryx, Inc. - Form 10-Q

ten-year term to purchase 150,000 shares of the Company's common stock at an exercise price per share equal to \$20.00 per share, or 200% of the IPO price of its common stock. In addition, pursuant to the terms of the convertible note loan agreement, concurrent with the IPO, Techno purchased \$5.0 million of the Company's common stock in a private placement at \$10.00 per share.



**Table of Contents****7. Shareholders' Equity****Initial Public Offering**

In February 2012, the Company completed its IPO pursuant to which the Company issued 5,175,000 shares of common stock, including the exercise of the underwriters' over-allotment option and received (a) net proceeds of \$45.0 million, after underwriting discounts, commissions and offering expenses; and (b) gross proceeds of \$12.0 million in concurrent private placements of 1,200,000 shares of common stock at the IPO price of \$10.00 per share. In addition, in connection with the completion of the Company's IPO, all convertible preferred stock converted into 24,332,186 shares of common stock. As discussed in Note 6, all outstanding principal and accrued and unpaid interest under the convertible note loan agreement with Techne also converted into common stock upon the completion of the Company's IPO.

**Warrants to Purchase Common Stock**

In February 2012, in connection with the IPO, the warrants to purchase Series B convertible preferred stock converted into warrants to purchase 159,500 shares of common stock at \$5.20 per share, with expiration dates from 2012 through 2014. As discussed in Note 6, upon the completion of the Company's IPO in February 2012, Techne received a warrant with a ten-year term to purchase 150,000 shares of the Company's common stock at \$20.00 per share. As of December 31, 2012, warrants to purchase 301,672 shares of common stock were outstanding with a weighted-average exercise price of \$12.56. During the three months ended March 31, 2013, warrants to purchase 150,000 shares of common stock were exercised. As of March 31, 2013, warrants to purchase 151,672 shares of common stock were outstanding with a weighted-average exercise price of \$19.84.

**8. Equity Incentive Plans**

During the three months ended March 31, 2013, the Company had the following option activities under its equity incentive plans:

	Available for Grant	Shares	Weighted Average Exercise Price	Outstanding Options	
				Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
Balance at December 31, 2012	1,567,902	5,292,738	\$ 7.38		
Shares authorized	1,450,000				
Granted	(62,075)	62,075	12.02		
Exercised	0	(371,247)	3.48		
Forfeited	13,794	(13,794)	9.29		
Balance at March 31, 2013	2,969,621	4,969,772	\$ 7.73	6.70 years	\$ 30,897,334

**Stock-based Compensation**

Total stock-based compensation expense was \$1.5 million during the three months ended March 31, 2013 and \$1.0 million during the three months ended March 31, 2012. As of March 31, 2013, \$11.5 million of total unrecognized compensation expense related to employee stock options, net of estimated forfeitures, was expected to be recognized over a weighted-average period of 2.67 years.

**9. Subsequent Event**

In April 2013, the Company completed an underwritten public offering of 5,750,000 shares of its common stock at \$12.00 per share. The Company received net proceeds of approximately \$64.4 million, after deducting underwriting discounts, commissions and estimated offering expenses.



## **Table of Contents**

### **Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*The following discussion and analysis should be read in conjunction with our financial statements and accompanying notes included in this Quarterly Report on Form 10-Q and the financial statements and accompanying notes thereto and Management's Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2012, filed with the Securities and Exchange Commission, or SEC, on March 14, 2013.*

#### **Forward-Looking Statements**

This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as may, could, will, would, should, expect, plan, aim, anticipate, believe, predict, seek, contemplate, potential or continue or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:

the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs;

our ability to advance drug candidates into, and successfully complete, clinical trials;

our collaborator's exercise of its option with respect to CCX168;

the commercialization of our drug candidates;

the implementation of our business model, strategic plans for our business, drug candidates and technology;

the scope of protection we are able to establish and maintain for intellectual property rights covering our drug candidates and technology;

estimates of our expenses, future revenues, capital requirements and our needs for additional financing;

the timing or likelihood of regulatory filings and approvals;

our ability to maintain and establish collaborations or obtain additional government grant funding;

our financial performance; and

developments relating to our competitors and our industry.

These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those included in Item 1A. Risk Factors in our Annual Report on Form 10-K for the fiscal year ended

## Edgar Filing: ChemoCentryx, Inc. - Form 10-Q

December 31, 2012, filed with the SEC on March 14, 2013.

Any forward-looking statement in this Quarterly Report on Form 10-Q reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. For all forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

ChemoCentryx<sup>®</sup>, the ChemoCentryx logo, Traficet and Traficet-EN are our trademarks in the United States, the European Community, Australia and Japan. EnabaLink<sup>®</sup> and RAM<sup>®</sup> are our trademarks in the United States. Each of the other trademarks, trade names or service marks appearing in this Quarterly Report on Form 10-Q belongs to its respective holder.

Unless the context requires otherwise, in this Quarterly Report on Form 10-Q the terms ChemoCentryx, we, us and our refer to ChemoCentryx, Inc., a Delaware corporation, and our subsidiary taken as a whole.

---

## Table of Contents

### Overview

ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. We currently have six drug candidates in clinical development. Our drug candidates include:

Vercirmon (the FDA United States Adopted Name, or USAN designation; also known as Traficet-EN, CCX282 or GSK1605786) Our most advanced drug candidate targets the chemokine receptor known as CCR9 and is currently in four pivotal Phase III clinical trials being conducted by our partner Glaxo Group Limited, or GSK, an affiliate of GlaxoSmithKline, for the treatment of patients with moderate-to-severe Crohn's disease;

CCX140 Our lead independent drug candidate targets the chemokine receptor known as CCR2 and is currently in Phase II clinical trials in patients with diabetic nephropathy, a form of kidney disease;

CCX354 (GSK2941266) An inhibitor of the chemokine receptor known as CCR1, successfully completed a Phase II proof-of-concept clinical trial for the treatment of rheumatoid arthritis, or RA, and was subsequently licensed exclusively to GSK, now solely responsible for further clinical development;

CCX168 Targeting the chemoattractant receptor known as C5aR (which binds the complement fragment C5a), CCX168 is currently in a Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody, or ANCA, associated vasculitis, and subject to GSK's option in 2013 if it meets the success criteria established by the joint steering committee, or JSC;

CCX872 Our independent next generation of orally administered inhibitors targeting CCR2 for expanded indications of renal disease is currently in Phase I clinical development; and

CCX507 Our *de novo* wholly-owned next generation CCR9 inhibitor for inflammatory bowel disease and related disorders is currently in Phase I clinical development.

CCX140, CCX872 and CCX507 are wholly owned and are being developed independently by us, while vercirmon, CCX354 and CCX168 are subject to our collaboration agreement with GSK. In December 2009 and November 2011, GSK exercised its options to obtain exclusive licenses for the further development and commercialization of vercirmon and CCX354, respectively. Upon exercise of these options, GSK assumed sole responsibility for the further development and commercialization of these drug candidates and each of their two respective back-up compounds. We are also advancing several additional independent drug candidates through preclinical development. In addition, our strategy has been to identify next generation compounds related to our drug candidates. All of our drug candidates, including those under our collaboration agreement with GSK, have been internally discovered.

In August 2006, we entered into our strategic alliance with GSK. We have received over \$250 million from GSK, of which approximately \$82 million was in the form of equity investments, and the balance from up-front and milestone payments, research funding and option exercise fees. Under the terms of our agreement with GSK, we are responsible for the discovery and development of small molecule antagonists targeting four defined chemokine and chemo-attractant receptor targets (CCR9, CCR1, C5aR and ChemR23) and for advancing them through clinical proof-of-concept or to such other success criteria as are established by the JSC. If we demonstrate the satisfaction of the applicable success criteria, GSK is entitled to options to exclusively license drug candidates that are subject to the collaboration and two defined back-up compounds for each drug candidate for further development and commercialization on a worldwide basis. Upon exercising any of its options to drug candidates under the collaboration, GSK is solely responsible for all further clinical development and commercialization expenditures worldwide with respect to that drug candidate and its two designated back-up compounds. In exchange for the rights granted to GSK upon the exercise of its options, we are also entitled to receive regulatory and commercial milestone payments, as earned under the terms of our agreement, and royalties on the net sales of licensed drugs. GSK has already exercised its options to vercirmon (CCR9) and CCX354 (CCR1) and each of their two respective defined back-up compounds and we and GSK determined not to further advance the development of CCX832 (ChemR23) or its two designated back-up compounds. Thus, GSK's only remaining option is to CCX168 (C5aR) and its associated back-up

## Edgar Filing: ChemoCentryx, Inc. - Form 10-Q

compounds. If GSK does not exercise its option to CCX168, we will evaluate our alternatives for further development of this drug candidate, which may entail internally developing it or identifying other collaboration partners for its development.

Since commencing our operations in 1997, our efforts have focused on research, development and the advancement of our drug candidates into and through clinical trials. As a result, we have incurred significant losses. We have funded our operations primarily through the sale of convertible preferred and common stock, contract revenue under our collaborations, government contracts and grants and borrowings under equipment financing arrangements. In February 2012, we completed our IPO pursuant to which we received net proceeds of \$45.0 million, after underwriting discounts, commissions and offering expenses. We also received gross proceeds of \$12.0 million from concurrent private placements of common stock at the IPO price of \$10.00 per share. In addition, the outstanding principal amount of \$10.0 million and accrued interest under a convertible note we had issued to Techne Corporation, or Techne, one of our principal stockholders, automatically converted into shares of our common stock in connection with our IPO at a conversion price equal to the IPO price. In April 2013, we completed an underwritten public offering of 5,750,000 shares of our

**Table of Contents**

common stock at \$12.00 per share. The Company received net proceeds of approximately \$64.4 million, after deducting underwriting discounts, commissions and estimated offering expenses. As of March 31, 2013, we had an accumulated deficit of \$144.4 million. We expect to continue to incur net losses as we develop our drug candidates, expand clinical trials for our drug candidates currently in clinical development, expand our research and development activities, expand our systems and facilities, seek regulatory approvals and engage in commercialization preparation activities in anticipation of Food and Drug Administration, or FDA, approval of our drug candidates. In addition, if a product is approved for commercialization, we will need to expand our organization. Significant capital is required to launch a product and many expenses are incurred before revenues are received. We are unable to predict the extent of any future losses or when we will become profitable, if at all.

**JOBS Act**

In April 2012, the JOBS Act was enacted. Section 107 of the JOBS Act provides that an emerging growth company can utilize the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for implementing new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to delay such adoption of new or revised accounting standards, and as a result, we may not implement new or revised accounting standards on the relevant dates on which adoption of such standards is required for other companies.

Subject to certain conditions set forth in the JOBS Act, as an emerging growth company, we intend to rely on certain of these exemptions, including without limitation, providing an auditor's attestation report on our system of internal controls over financial reporting pursuant to Section 404 and implementing any requirement that may be adopted regarding mandatory audit firm rotation or a supplement to the auditor's report providing additional information about the audit and the financial statements (auditor discussion and analysis). These exemptions will apply for a period of five years following the completion of our IPO although if the market value of our common stock that is held by nonaffiliates exceeds \$700 million as of any June 30 before that time, we would cease to be an emerging growth company as of the following December 31.

**Critical Accounting Policies and Significant Judgments and Estimates**

There have been no material changes in our critical accounting policies during the three months ended March 31, 2013, as compared to those disclosed in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations Critical Accounting Policies and Significant Judgments and Estimates in our Annual Report on Form 10-K for the fiscal year ended December 31, 2012, filed with the SEC on March 14, 2013.

**Results of Operations****Revenue**

We have not generated any revenue from product sales. For the three months ended March 31, 2013, our revenue was derived from the recognition of up-front payments and reimbursement for research and development services from GSK. Total revenues for the period, as compared to the same period in the prior year, were as follows (in thousands):

	<b>Three Months Ended March 31,</b>	
	<b>2013</b>	<b>2012</b>
<b>GSK:</b>		
Contract revenue	\$ 799	\$
Recognition of up-front payments	1,128	1,018
 Total revenues	 \$ 1,927	 \$ 1,018
 Dollar increase	 909	
Percentage increase	89%	

The increase in revenues from 2012 to 2013 for the three month period was primarily due to funding of clinical support from GSK for CCX168 and, to a lesser extent, an increase in revenue relating to the upfront payment from GSK following our decision not to advance CCX832, thereby shortening the term of our performance obligation and associated period over which the upfront payment is recognized.





**Table of Contents*****Research and development expenses***

Research and development expenses represent costs incurred to conduct basic research the discovery and development of novel small molecule therapeutics, such as vercirnon and CCX140; the development of our suite of proprietary drug discovery technologies, known collectively as EnabaLink, which includes our proprietary Reverse Activation of Migration, or RAM, screening technology and preclinical studies and clinical trials of our drug candidates. We expense all research and development expenses as they are incurred. These expenses consist primarily of salaries and related benefits, including stock-based compensation, third-party contract costs relating to research, formulation, manufacturing, preclinical study and clinical trial activities, laboratory consumables, and allocated facility costs. Total research and development expenses for the period, as compared to the same period in the prior year, were as follows (in thousands):

	<b>Three Months Ended March 31,</b>	
	<b>2013</b>	<b>2012</b>
Research and development expenses	\$ 9,255	\$ 6,909
Dollar increase	\$ 2,346	
Percentage increase		34%

The increase in expense from 2012 to 2013 for the three month period was primarily due to investing in our lead independent program targeting the chemokine receptor known as CCR2, including the advancement of CCX872, our second generation CCR2 inhibitor, into Phase I clinical development and CCX140 in Phase II studies in patients with diabetic nephropathy. In addition, CCX168 associated expenses increased primarily due to the continued patient enrollment in our Phase II clinical trial for the treatment of ANCA vasculitis. These increases were partially offset by a decrease in expenses associated with drug discovery efforts targeting CXCR7.

We track specific project expenses that are directly attributable to our clinical development candidates and preclinical candidates that have been nominated and selected for further development. Such project specific expenses include third-party contract costs relating to formulation, manufacturing, preclinical studies and clinical trial activities. Unlike our early stage research and drug discovery programs, we allocate research and development salaries, benefits or indirect costs to our development candidates and we have included such costs in the project specific expenses. All remaining research and development expenses are reflected in Other which represents early stage drug discovery programs. Such expenses include allocated employee salaries and related benefits, stock-based compensation, consulting and contracted services to supplement our in-house laboratory activities, laboratory consumables and allocated facility costs associated with these earlier stage programs.

**Table of Contents**

At any given time, we typically have several active early stage research and drug discovery projects. Our internal resources, employees and infrastructure are not directly tied to any individual research or drug discovery project and are typically deployed across multiple projects. As such, we do not maintain information regarding these costs incurred for our early stage research and drug discovery programs on a project specific basis. The following table summarizes our research and development expenses by project (in thousands):

	Three Months Ended March 31,	
	2013	2012
Development candidate (Target)		
CCX140 (CCR2)	\$ 2,722	\$ 2,642
CCX872 (CCR2 2G)	1,663	607
CCX168 (C5aR)	978	396
CCX507 (CCR9 de novo)	759	734
CCX650 (CXCR7)	188	1,042
CCX354 (CCR1)		109
CCX832 (ChemR23) <sup>(1)</sup>		91
Other (CCR2 3G, CCR6, CCR4, CXCR6, Other)	2,945	1,288
Total research and development	\$ 9,255	\$ 6,909

(1) In February 2012, we and GSK determined not to further advance the development of CCX832 or its two designated back-up compounds. We expect our research and development expenses to increase as we advance our development programs further and increase the number and size of our clinical trials. The process of conducting preclinical studies and clinical trials necessary to obtain regulatory approval is costly and time consuming. We or our partners may never succeed in achieving marketing approval for any of our drug candidates. The probability of success for each drug candidate may be affected by numerous factors, including preclinical data, clinical data, competition, manufacturing capability and commercial viability. For the remaining product option covered under our strategic alliance with GSK, for which we are eligible to receive milestone payments, we are responsible for development of drug candidates through satisfaction of the success criteria mutually agreed upon by the members of the JSC under this strategic alliance, after which time GSK has an option to an exclusive license on a compound by compound basis. Our strategy includes entering into additional partnerships with third parties for the development and commercialization of some of our independent drug candidates that are not subject to our alliance with GSK.

Most of our product development programs are at an early-to-mid-stage; therefore the successful development of our drug candidates is highly uncertain and may not result in approved products. Completion dates and completion costs can vary significantly for each drug candidate and are difficult to predict for each product. Given the uncertainty associated with clinical trial enrollments and the risks inherent in the development process, we are unable to determine the duration and completion costs of the current or future clinical trials of our drug candidates or if, or to what extent, we will generate revenues from the commercialization and sale of any of our drug candidates. We anticipate we will make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis in response to the scientific and clinical success of each drug candidate, as well as ongoing assessment as to each drug candidate's commercial potential. We will need to raise additional capital or may seek additional strategic alliances in the future in order to complete the development and commercialization of our drug candidates, including CCX140, our lead independent drug candidate.

**Table of Contents****General and administrative expenses**

Total general and administrative expenses were as follows (in thousands):

	<b>Three Months Ended March 31,</b>	
	<b>2013</b>	<b>2012</b>
General and administrative expenses	\$ 2,964	\$ 2,562
Dollar increase	\$ 402	
Percentage increase	16%	

General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation and travel expenses, in executive, finance, business and corporate development and other administrative functions. Other general and administrative expenses include allocated facility-related costs not otherwise included in research and development expenses, legal costs of pursuing patent protection of our intellectual property, and professional fees for auditing, tax, and legal services.

The increases from 2012 to 2013 for the three month period were primarily due to increased stock based compensation expense for stock option grants in addition to higher professional service fees relating to fulfilling our reporting obligations as a public company. We expect that general and administrative expenses will increase in the future as we expand our operating activities and incur additional costs associated with being a public company. These public company related increases will likely include investor and public relations expenses and legal and accounting related fees and expenses associated with preparing the Company to meet the requirements pursuant to the Sarbanes-Oxley Act of 2002.

**Interest and other income (expense)**

Interest and other income (expense), primarily consists of interest income earned on our marketable securities and interest expense incurred on our equipment financing obligations and our convertible note. Total interest and other income (expense), net, as compared to prior years was as follows (in thousands):

	<b>Three Months Ended March 31,</b>	
	<b>2013</b>	<b>2012</b>
Interest income	\$ 116	\$ 103
Interest expense	(17)	(735)
<b>Total interest income (expense) and other income, net</b>	<b>\$ 99</b>	<b>\$ (632)</b>
Dollar increase	731	
Percentage increase	-116%	

Interest expense for the three months ended March 31, 2013 was primarily related to our interest expense due on our equipment lines of credit. Interest expense decreased from 2012 to 2013 for the three month period primarily due to the automatic conversion of the convertible note issued to Techne to common stock upon our IPO in February 2012. Prior to its conversion, the change in the estimated fair value of the convertible note was recorded as interest expense.

**Liquidity and Capital Resources**

As of March 31, 2013, we had approximately \$109.7 million in cash, cash equivalents and investments. Such balances exclude the net proceeds of approximately \$64.4 million, after deducting underwriting discounts, commissions and estimated offering expenses, from the aforementioned underwritten public offering of 5,750,000 shares of our common stock at \$12.00 per share in April 2013.

**Table of Contents**

The following table shows a summary of our cash flows for the three months ended March 31, 2013 and 2012 (in thousands):

	Three Months Ended March 31,	
	2013	2012
Cash provided by (used in)		
Operating activities	\$ (10,266)	\$ (6,399)
Investing activities	11,979	(70,059)
Financing activities	1,464	57,036

*Operating activities.* Net cash used in operating activities was \$10.3 million for the three months ended March 31, 2013, compared to net cash used of \$6.4 million for the same period in 2012. This change was primarily due to changes in working capital items and an increase in net loss in the 2013 period.

*Investing activities.* Net cash used in or provided by investing activities for periods presented primarily relate to the purchase, sale and maturity of investments used to fund the day-to-day needs of our business. Following our February 2012 IPO, we invested the majority of our net proceeds received in short and long term investments. We finance property and equipment purchases through equipment financing facilities. Proceeds from collaboration agreements and common stock issuances are used for general working capital purposes, such as research and development activities and other general corporate purposes.

*Financing activities.* Net cash provided by financing activities was \$1.5 million for the three months ended March 31, 2013, compared to \$57.0 million for the same period in 2012. This decrease was primarily due to \$57.0 million in net proceeds from the issuance of common stock as a result of our IPO and concurrent private placements in February 2012.

We believe that our existing cash, cash equivalents and investments as of March 31, 2013 will be sufficient to meet our anticipated cash requirements for at least the next 12 months. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially.

Our future capital requirements are difficult to forecast and will depend on many factors, including:

the achievement of milestones under our agreement with GSK;

the terms and timing of any other collaborative, licensing and other arrangements that we may establish;

the initiation, progress, timing and completion of preclinical studies and clinical trials for our drug candidates and potential drug candidates;

the number and characteristics of drug candidates that we pursue;

the progress, costs and results of our clinical trials;

the outcome, timing and cost of regulatory approvals;

delays that may be caused by changing regulatory approvals;

## Edgar Filing: ChemoCentryx, Inc. - Form 10-Q

the cost and timing of hiring new employees to support continued growth;

the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims;

the cost and timing of procuring clinical and commercial supplies of our drug candidates;

the cost and timing of establishing sales, marketing and distribution capabilities; and

the extent to which we acquire or invest in businesses, products or technologies.

### **Contractual Obligations and Commitments**

There have been no material changes outside the ordinary course of our business to the contractual obligations we reported in our Annual Report on Form 10-K for the fiscal year ended December 31, 2012 filed with the SEC on March 14, 2013.

### **Item 3. Quantitative and Qualitative Disclosures About Market Risk**

Our market risks at March 31, 2013 have not changed significantly from those discussed in Item 7A. Quantitative and Qualitative Disclosures About Market Risk of our Annual Report on Form 10-K for the fiscal year ended December 31, 2012, filed with the SEC on March 14, 2013.

**Table of Contents**

**Item 4. Controls and Procedures**

**Conclusions Regarding the Effectiveness of Disclosure Controls and Procedures**

As of March 31, 2013, management, with the participation of our Disclosure Committee, performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures.

Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of March 31, 2013, the design and operation of our disclosure controls and procedures were effective.

**Changes in Internal Control Over Financial Reporting**

There has been no change in our internal control over financial reporting during the three month period ended March 31, 2013, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

**Table of Contents**

**PART II. OTHER INFORMATION**

**Item 1. Legal Proceedings**

Not Applicable.

**Item 1A. Risk Factors**

There have been no material changes to the risk factors included in Item 1A. Risk Factors in our Annual Report on Form 10-K for the fiscal year ended December 31, 2012, filed with the SEC on March 14, 2013.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

**Unregistered Sales of Equity Securities**

None.

**Use of Proceeds**

In February 8, 2012, our registration statement on Form S-1 (File No. 333-177332), which registered an aggregate amount of up to \$73.6 million of our common stock, was declared effective by the SEC for our IPO pursuant to which we sold 5,175,000 shares of common stock at an IPO price of \$10.00 per share, including the exercise of the underwriters' over-allotment option. As a result of the IPO, we received gross proceeds of approximately \$51.8 million, which resulted in net proceeds to us of approximately \$45.0 million, after underwriting expenses of approximately \$6.8 million (comprising \$3.6 million of underwriting discounts and commissions and \$3.2 million in other offering expenses). None of the expenses associated with the IPO were paid to directors, officers, persons owning ten percent or more of any class of equity securities, or to their associates, or to our affiliates.

We intend to use the net offering proceeds to advance our independent drug candidates through the clinic and for working capital and general corporate purposes. Through March 31, 2013, the net proceeds have been applied as follows: \$14.5 million to further develop CCX140, \$4.8 million to advance CCX168 and CCX650, \$9.4 million to advance CCX872 and CCX507 into clinical development and \$11.0 million to fund other research and drug discovery programs. Pending use of the net proceeds, we intend to invest the net proceeds in short and intermediate-term, interest-bearing obligations, in investment grade securities, or in high credit quality U.S. government agency obligations and commercial paper. There has been no material change in the planned use of proceeds from our IPO from that described in the final prospectus filed with the SEC pursuant to Rule 424(b) on February 9, 2012.

**Item 3. Defaults Upon Senior Securities**

Not Applicable.

**Item 4. Mine Safety Disclosures**

Not Applicable.

**Item 5. Other Information**

Not Applicable.

**Item 6. Exhibits**

A list of exhibits is set forth on the Exhibit Index immediately following the signature page of this Quarterly Report on Form 10-Q, and is incorporated herein by reference.





**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**CHEMOCENTRYX, INC.**

Date: May 14, 2013

/s/ Thomas J. Schall, Ph.D.  
Thomas J. Schall, Ph.D.

President and Chief Executive Officer

(Principal Executive Officer)

Date: May 14, 2013

/s/ Susan M. Kanaya  
Susan M. Kanaya

Senior Vice President, Finance,

Chief Financial Officer and Secretary

(Principal Financial and Accounting Officer)

**Table of Contents**

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>
3.1(1)	Amended and Restated Certificate of Incorporation.
3.2(1)	Amended and Restated Bylaws.
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101*	The following information from the Registrant's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2013, formatted in XBRL (Extensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statements of Comprehensive Loss, (iv) Condensed Consolidated Statements of Cash Flows, and (v) the Notes to Condensed Consolidated Financial Statements.
(1)	Filed with Amendment No. 3 to the Registrant's Registration Statement on Form S-1 on January 23, 2012 (Registration No. 333-177332), and incorporated herein by reference.
*	Users of this data are advised that pursuant to Rule 406T of Regulation S-T, this XBRL information is being furnished and not filed herewith for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and Sections 11 or 12 of the Securities Act of 1933, as amended, and is not to be incorporated by reference into any filing, or part of any registration statement or prospectus, of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.